ProtoKinetix Inc (PKTX)

[SPORT19]

2 years since this BS!!!!!

Scumbags


September 15, 2020

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or
"ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company,
today announced that after the conclusion of 4-years of extensive
testing, evidence of fully functional retinal cells was conclusively
achieved. Based on these results Dr. Kevin Gregory-Evans will submit a
paper for publication in a peer reviewed journal.

In vivo ((Latin for "within the living") tests demonstrated that
transplantation of Precursor Photo Cells (PPC)s pre-treated with AAGP®
(PKX-001) results in statistically significant improvements in both
the visual behavioral (optokinetic tracking test) and functional
analysis (electroretinogram test) responses as compared with PPCs
without pretreatment. Imaging data revealed that pre-treatment of PPCs
with AAGP® also leads to a substantial enhancement of cell survival as
determined at 3, 4.5 and 6 months after cell transplantation. At the
6-month time point, the AAGP®-treated cells acquired the ability to
express retinal and synaptic proteins, confirming that AAGP® has no
adverse effect on precursor cells’ maturation. (PPCs are used in AMD
study.)

Macular degeneration, or age-related macular degeneration (AMD), is a
leading cause of vision loss in Americans 60 and older. It is a
disease that destroys sharp, central vision. Central vision is crucial
for seeing objects clearly and doing tasks such as reading and
driving. AMD affects the macula, which is the part of the eye that
allows you to see fine detail. AMD does not hurt, but it causes cells
in the macula to die. There are two types of AMD: wet and dry. Wet AMD
happens when abnormal blood vessels grow under the macula. These new
blood vessels often leak blood and fluid. Wet AMD damages the macula
quickly. Blurred vision is a common early symptom. Dry AMD happens
when the light-sensitive cells in the macula slowly break down
resulting in the loss of central vision.

The study was conducted by the Gregory-Evans Retinal Therapeutic Lab
at the University of British Columbia. "We are very excited by these
latest results showing functional benefits with these AAGP®-pre
treated stem cells”. – Dr. Kevin Gregory-Evans

The success of these tests opens doors for ProtoKinetix AAGP® in the
entire field of regenerative medicine. The next step towards
commercialization is partnering with a major pharma to adapt AAGP®
into their current clinical trial program. The global ophthalmic
therapeutics/drug market is expected to reach USD $35.7 billion by
2025, according to a new report by Grand View Research, Inc.

In addition, for an update on our ocular dry eye disease and ocular
inflammation program, go to the ProtoKinetix's web-site and click on
"Novel Treatment for Dry Eye Disease"